Chris Shibutani
Stock Analyst at Goldman Sachs
(3.59)
# 769
Out of 5,182 analysts
94
Total ratings
56.25%
Success rate
24.94%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $60.10 | +66.39% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $16.94 | -82.29% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $8.76 | +71.23% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $34.77 | -7.97% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $92.08 | +48.78% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $24.56 | +34.36% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $581.69 | -48.08% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $47.90 | +6.47% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $241.30 | -35.76% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $16.92 | -76.36% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $5.86 | +241.30% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $953.30 | -24.16% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $11.50 | +126.09% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $133.15 | +14.91% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $211.59 | -18.24% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $75.08 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $59.20 | +16.55% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $23.62 | -44.96% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $96.75 | -76.23% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $87.13 | -40.32% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $27.47 | +118.42% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $14.32 | +25.70% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $20.06 | -15.25% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.10 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.51 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $60.10
Upside: +66.39%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $16.94
Upside: -82.29%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $8.76
Upside: +71.23%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $34.77
Upside: -7.97%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $92.08
Upside: +48.78%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $24.56
Upside: +34.36%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $581.69
Upside: -48.08%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $47.90
Upside: +6.47%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $241.30
Upside: -35.76%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $16.92
Upside: -76.36%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $5.86
Upside: +241.30%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $953.30
Upside: -24.16%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $11.50
Upside: +126.09%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $133.15
Upside: +14.91%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $211.59
Upside: -18.24%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $75.08
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $59.20
Upside: +16.55%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $23.62
Upside: -44.96%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $96.75
Upside: -76.23%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $87.13
Upside: -40.32%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $27.47
Upside: +118.42%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $14.32
Upside: +25.70%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $20.06
Upside: -15.25%
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $6.10
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $7.51
Upside: -